Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Medicines Co. Prepares To Move Into New Commercial Territory

This article was originally published in The Pink Sheet Daily

Executive Summary

With the release of positive Phase III data on the antibiotic oritavancin, the hospital specialist soon could be making a commercial foray into an area outside its current expertise in cardiovascular disease.

Advertisement

Related Content

Oritavancin Phase III Results Support FDA’s New Endpoint, Sponsor Says
Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value
With GAIN In Place, Antibiotic Improvements Depend On FDA Implementation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel